- Home
- CGEN vs FORR Comparison
CGEN vs FORR Comparison
Compare CGEN & FORR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | CGEN | FORR |
|---|---|---|
| Founded | 1993 | 1983 |
| Country | Israel | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Diversified Commercial Services |
| Sector | Health Care | Consumer Discretionary |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 143.1M | 131.7M |
| IPO Year | 2000 | 1996 |
Fundamental Metrics
Financial Performance| Metric | CGEN | FORR |
|---|---|---|
| Price | $1.48 | $7.66 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | ★ 405.6K | 95.7K |
| Earning Date | 11-10-2025 | 02-10-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | $6,903,000.00 | ★ $403,871,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $231.15 | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $1.13 | $6.60 |
| 52 Week High | $2.66 | $16.10 |
Technical Indicators
Market Signals| Indicator | CGEN | FORR |
|---|---|---|
| Relative Strength Index (RSI) | 40.30 | 58.59 |
| Support Level | $1.47 | $6.97 |
| Resistance Level | $1.55 | $7.57 |
| Average True Range (ATR) | 0.07 | 0.24 |
| MACD | -0.00 | 0.09 |
| Stochastic Oscillator | 16.98 | 91.57 |
Price Performance
Historical ComparisonAbout CGEN Compugen Ltd.
Compugen Ltd is a clinical-stage therapeutic discovery and development company utilizing its broadly applicable predictive computational discovery capabilities to identify novel drug targets and new biological pathways to develop therapeutics in the field of cancer immunotherapy. Its immuno-oncology pipeline consists of four clinical-stage programs, targeting immune checkpoints the company discovered computationally, COM701, COM902 and bapotulimab. The company's therapeutic pipeline of early-stage immuno-oncology programs consists of programs aiming to address various mechanisms of immune resistance, including myeloid targets.
About FORR Forrester Research Inc.
Forrester Research Inc provides independent research, data, and advisory services. It operates through the following segments: The Research segment develops and delivers research, connect, and analytics products; The consulting segment includes the revenues and the related costs of the company's consulting organization, and the Events segment is engaged in developing and hosting in-person and virtual events.